BioNTech starts Covid-19 vaccine production at new Marburg plant
BioNTech has started production of its Covid-19 vaccine from a new manufacturing site in Marburg, Germany.
Biontech SE ADR
$0.00
15:49 12/04/24
0.00%
$0.00
BIONTECH SP ADS
$92.72
12:55 03/05/24
0.52%
$0.48
Pfizer Inc.
$27.81
11:10 03/05/24
0.40%
$0.11
At full capacity, the new installation will be able to make 750m doses of the vaccine annually, with the first distribution of vaccines from Marburg currently penciled-in for April.
Together with Pfizer, its partner in developing the vaccine, BioNTech is targeting full-year vaccine production of 2bn doses.
BioNTech's expected vaccine output in the first half of 2021 is expected to reach 250m doses.